Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TOLERANCE OF DOLUTEGRAVIR VERSUS RALTEGRAVIR COMBINED WITH TENOFOVIR DISOPROXIL AND EMTRICITABINE OR LAMIVUDINE AS POSTEXPOSURE PROPHYLAXIS AGAINST HIV INFECTION

Next Previous
Trial Profile

TOLERANCE OF DOLUTEGRAVIR VERSUS RALTEGRAVIR COMBINED WITH TENOFOVIR DISOPROXIL AND EMTRICITABINE OR LAMIVUDINE AS POSTEXPOSURE PROPHYLAXIS AGAINST HIV INFECTION

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 01 Aug 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dolutegravir (Primary) ; Raltegravir (Primary) ; Emtricitabine; Lamivudine; Tenofovir disoproxil fumarate
  • Indications HIV infections
  • Focus Adverse reactions
  • Acronyms DoRa

Most Recent Events

  • 21 Apr 2018 Status changed from not yet recruiting to planning.
  • 17 Apr 2018 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top